Yahoo! Finance: KERX News

3 Stocks Ready to Roar (at Motley Fool)

Tue, 29 Dec 2009 19:45:38 Etc/GMT

UPDATE - Aeterna, Sanofi end prostate drug pact (at Reuters)

Fri, 18 Dec 2009 13:14:26 Etc/GMT

KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events (EDGAR Online)

Thu, 17 Dec 2009 22:15:45 Etc/GMT

KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events (EDGAR Online)

Wed, 16 Dec 2009 22:01:47 Etc/GMT

Technitrol, Sycamore: Early Volume Plays (at TheStreet.com)

Wed, 16 Dec 2009 14:13:13 Etc/GMT

Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma (PR Newswire)

Wed, 16 Dec 2009 13:30:00 Etc/GMT

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 , the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients.

KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events (EDGAR Online)

Mon, 7 Dec 2009 22:06:34 Etc/GMT

UPDATE - Aeterna's prostate treatment misses key goal (at Reuters)

Mon, 7 Dec 2009 17:27:50 Etc/GMT

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology (PR Newswire)

Mon, 7 Dec 2009 13:30:00 Etc/GMT

Keryx Biopharmaceuticals, Inc. today announced updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Generic Drugs Continue To Accelerate Market Share Expansion According To Sanford Bernstein (Wall Street Transcript)

Mon, 7 Dec 2009 13:18:00 Etc/GMT

67 WALL STREET, New York - December 7, 2009 - The Wall Street Transcript has just published its Consumer Health Services Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Stock Watch: InvestorSoup.com Issues Market Alert for Keryx Pharmaceuticals Inc. (GlobeNewswire)

Thu, 3 Dec 2009 12:30:00 Etc/GMT

DALLAS -- InvestorSoup.com announces an investment report featuring Keryx Biopharmaceuticals Inc. . The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events (EDGAR Online)

Wed, 2 Dec 2009 22:01:53 Etc/GMT

Keryx treatment gets faster FDA review (AP)

Wed, 2 Dec 2009 20:42:04 Etc/GMT

Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.

Skymark Research Initiates Independent Research Coverage on Keryx Biopharmaceuticals, Inc. (GlobeNewswire)

Wed, 2 Dec 2009 14:55:17 Etc/GMT

CALGARY, Alberta -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Keryx Biopharmaceuticals, Inc. . Skymark Research is currently offering a complimentary trial subscription.

UPDATE - FDA fast tracks Aeterna, Keryx cancer drug (at Reuters)

Wed, 2 Dec 2009 14:20:48 Etc/GMT

Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma (PR Newswire)

Wed, 2 Dec 2009 13:30:00 Etc/GMT

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation for KRX-0401 , the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase /Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

Still Believe in Antigenics (at Seeking Alpha)

Tue, 24 Nov 2009 21:19:42 Etc/GMT

Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference (PR Newswire)

Tue, 24 Nov 2009 13:30:00 Etc/GMT

Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference being held in New York City.

KERYX BIOPHARMACEUTICALS INC Financials (EDGAR Online Financials)

Sat, 14 Nov 2009 14:04:23 Etc/GMT

Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology (PR Newswire)

Wed, 11 Nov 2009 13:30:00 Etc/GMT

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 in combination with bortezomib has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology , to be held in New Orleans from December 5-8, 2009.